2. QUALITATIVE AND QUANTITATIVE COMPOSITION
The presence of the following factors may increase the risk of bleeding: e.g. age ≥75 years, moderate renal impairment (CrCl 30-50 ml/min), concomitant treatment with strong P-gp inhibitors
Download 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Statins: mechanism of action and effects
home.sandiego.eduIntroduction Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, have revolu-tionized the treatment of hypercholesterolemia.
Generic Stem Stem Definition Examples - Survive …
survivenursing.comDownloaded from Survive Nursing | survivenursing.com v20110426 Generic Stem Stem Definition Examples -abine (see -arabine, -citabine) decitabine-ac Anti -inflammatory agents (acetic acid derivatives) bromfenac; dexpemedol ac-acetam See -racetam
Definition, Example, Generic, Stem, Generic stem stem definition examples
DATA SHEET PRODUCT NAME - Medsafe
www.medsafe.govt.nzPage 1 of 15 DATA SHEET 1. PRODUCT NAME JANUVIA® 25 mg film-coated tablets JANUVIA® 50 mg film-coated tablets JANUVIA® 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each JANUVIA 25 mg tablet contains sitagliptin phosphate monohydrate, equivalent to 25 mg
Product, Name, Sheet, Data, Data sheet, Product name, Data sheet product name
Guidance for Industry - PortaCellTec
www.portacelltec.deGuidance for Industry Drug Interaction Studies — Study Design, Data Analysis, and Implications for Dosing and Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
Reversing the New Anticoagulants - UCSF Medical …
www.ucsfcme.com11/6/2013 7 Dabigatran Metabolism • Decreased effect with P-gP inducers • Rifampin • Increased effect with P-gP inhibitors • Dronedarone • Ketoconazole, Itraconazole • Verapamil • Amiodarone • Quinidine • Clarithromycin New Anticoagulants • Dabigatran (Pradaxa ®) • Rivaroxaban (Xarelto ®) • Apixaban (Eliquis ®) FACTOR Xa INHIBITORS …
Anticoagulant, Reversing, Inhibitors, Reversing the new anticoagulants
DOSING & MANAGEMENT GUIDE - Praxbind
www.praxbind.comSafety first—Immediate reversal available nationwide1,2 DOSING & MANAGEMENT GUIDE Please see Important Safety Information …